{'52WeekChange': -0.64219236,
 'SandP52WeekChange': 0.0644362,
 'address1': '301 Binney Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 3.53,
 'askSize': 800,
 'averageDailyVolume10Day': 335612,
 'averageVolume': 247736,
 'averageVolume10days': 335612,
 'beta': None,
 'beta3Year': None,
 'bid': 3.25,
 'bidSize': 1300,
 'bookValue': 2.938,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 3.62,
 'dayLow': 3.33,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -0.725,
 'enterpriseToRevenue': 14.247,
 'enterpriseValue': 78658936,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '617 890 6595',
 'fiftyDayAverage': 5.172143,
 'fiftyTwoWeekHigh': 14.83,
 'fiftyTwoWeekLow': 1.69,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 19423707,
 'forwardEps': -1.04,
 'forwardPE': -3.3269231,
 'fromCurrency': None,
 'fullTimeEmployees': 94,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.12579,
 'heldPercentInstitutions': 0.60418,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/cyclerion.com',
 'longBusinessSummary': 'Cyclerion Therapeutics, Inc., a clinical-stage '
                        'biopharmaceutical company, engages in the '
                        'discovering, development, and commercialization of '
                        'various treatments for serious and orphan diseases. '
                        'Its product candidates include Olinciguat, an orally '
                        'administered vascular soluble guanylate cyclase (sGC) '
                        'stimulator that is in Phase II studies for the '
                        'treatment of sickle cell disease (SCD); Praliciguat, '
                        'an orally administered systemic sGC stimulator that '
                        'is in Phase II trials for the treatment of diabetic '
                        'nephropathy and heart failure with preserved ejection '
                        'fraction; and IW-6463, an orally administered central '
                        'nervous system (CNS)-penetrant sGC stimulator, which '
                        'is in Phase I trials for neurodegenerative diseases. '
                        'The company is also discovering liver-targeted sGC '
                        'and lung-targeted sGC stimulators. Cyclerion '
                        'Therapeutics, Inc. was incorporated in 2018 and is '
                        'headquartered in Cambridge, Massachusetts.',
 'longName': 'Cyclerion Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 96031952,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_561493203',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -105855000,
 'nextFiscalYearEnd': 1640908800,
 'open': 3.57,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '857 327 8778',
 'previousClose': 3.64,
 'priceHint': 4,
 'priceToBook': 1.1776719,
 'priceToSalesTrailing12Months': 17.393942,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 3.62,
 'regularMarketDayLow': 3.33,
 'regularMarketOpen': 3.57,
 'regularMarketPreviousClose': 3.64,
 'regularMarketPrice': 3.57,
 'regularMarketVolume': 300484,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 27754900,
 'sharesPercentSharesOut': 0.0376,
 'sharesShort': 1042815,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 990185,
 'shortName': 'Cyclerion Therapeutics, Inc.',
 'shortPercentOfFloat': 0.042,
 'shortRatio': 3.25,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'CYCN',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -3.856,
 'twoHundredDayAverage': 4.0270863,
 'volume': 300484,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.cyclerion.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02142'}